Novel Proteoglycan Linkage Tetrasaccharides of Human Urinary Soluble Thrombomodulin, SO4-3GlcAbeta 1-3Galbeta 1-3(±Siaalpha 2-6)Galbeta 1-4Xyl*

Hiroyuki WakabayashiDagger §, Shunji NatsukaDagger , Tomohiro MegaDagger , Naoki OtsukiDagger , Mitsuko Isajiparallel , Masaaki Naotsuka**, Sadatoshi Koyama**, Toshinori Kanamori**, Kiyoshi Sakai**, and Sumihiro HaseDagger Dagger Dagger

From the Dagger  Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, ** Pharmaceutical Laboratory, Mochida Pharmaceutical Co., Ltd., Fujieda, Shizuoka 426-8640, and parallel  Biosciences Research Laboratory, Mochida Pharmaceutical Co., Ltd., Kita-ku, Tokyo 115-8515, Japan

    ABSTRACT
Top
Abstract
Introduction
References

O-linked sugar chains with xylose as a reducing end linked to human urinary soluble thrombomodulin were studied. Sugar chains were liberated by hydrazinolysis followed by N-acetylation and tagged with 2-aminopyridine. Two fractions containing pyridylaminated Xyl as a reducing end were collected. Their structures were determined by partial acid hydrolysis, two-dimensional sugar mapping combined with exoglycosidase digestions, methylation analysis, mass spectrometry, and NMR as SO4-3GlcAbeta 1-3Galbeta 1-3(±Siaalpha 2-6)Galbeta 1-4Xyl. These sugar chains could bind to an HNK-1 monoclonal antibody. This is believed to be the first example of a proteoglycan linkage tetrasaccharide with glucuronic acid 3-sulfate and sialic acid.

    INTRODUCTION
Top
Abstract
Introduction
References

Thrombomodulin (TM)1 is a physiologically important anticoagulant (1) that is present not only on the endothelial cell surface but also in soluble form in plasma and urine (2-4). Takahashi et al. (5) have purified the major active forms of human urinary soluble thrombomodulin (uTM) and demonstrated that they possess strong cofactor activity for thrombin-catalyzed protein C activation as well as exhibiting potent anticoagulant activity in vivo. They have also shown that uTM improves disseminated intravascular coagulation without excessive prolongation of the activated partial thromboplastin time (6). The protein possesses five potential N-linked glycosylation sites (7) as deduced from its amino acid sequence, whereas the detection of GalNAc suggests the presence of O-linked sugar chains (8). Although uTM does not contain a glycosaminoglycan, recombinant TM and some TMs obtained from cultured human endothelial cells are expressed in both a high molecular weight TM containing chondroitin sulfate and a low molecular weight TM lacking this modification (9, 10). Recombinant TM expressed in Chinese hamster ovary cells contains chondroitin 4-sulfate (11). TM glycosylation in relation to biological activity has been discussed in several papers (12-14), but to understand the structure and biological activities of the glycoprotein, detailed knowledge of the sugar structures is essential. Recently, the structures of N-linked sugar chains have been reported (15). During the course of studies on N- and O-linked sugar chains of uTM, we have detected new structures with xylose at the reducing ends. Here, we present a detailed analysis of the novel sugar structures found in uTM.

    EXPERIMENTAL PROCEDURES

Materials-- uTM was purified from human urine as reported previously (5). beta -Glucuronidase (bovine liver) was obtained from Sigma. Sialidase (Arthrobacter ureafaciens) was purchased from Nacalai Tesque (Kyoto), beta -galactosidase (Aspergillus sp.) from Toyobo (Osaka), actinase E from Kaken Pharmaceutical (Tokyo), chondro-4-sulfatase and chondro-6-sulfatase from Seikagaku Kogyo (Tokyo), and monoclonal HNK-1 antibody from Cosmo Bio (Tokyo). Galbeta 1-4Xyl-PA and GlcAbeta 1-3Galbeta 1-3Galbeta 1-4Xyl-PA were prepared as described (16). Standard partially O-methylated pyridylaminated (PA)-galactoses were prepared by pyridylamination of the corresponding partially O-methylated galactoses as reported (17). A Cosmosil 5C18-AR300 column (0.6 × 15 cm) was purchased from Nacalai Tesque, a Shodex NH2P-50 column (0.46 × 5 cm) from Showa Denko (Tokyo), a TSKgel sugar AXI column (0.46 × 7.5 cm) and Toyopearl HW-40F from Tosoh (Tokyo), Sephadex G-25, Sephadex LH-20, and a Mono Q HR 5/5 column from Amersham Pharmacia Biotech, a µBondasphere 5C18-300Å column (0.39 × 15 cm) from Nihon Waters (Tokyo), an IonPac AS4A column (0.4 × 25 cm) from Dionex (Sunnyvale, CA), a YMC-Pack Diol-200G column (0.8 × 50 cm) from YMC (Tokyo), DC-Alifolien silica gel 60 plates from Merck, Advantec 51B filter papers from Toyo Roshi (Tokyo), and Spectrapor membrane tubing (MWCO: 25,000) from Spectrum Medical Industries (Los Angeles, CA).

Preparation of Glycopeptides-- uTM (374 mg) was digested with 37 mg of actinase E in 3.7 ml of 0.2 M Tris-HCl buffer, pH 8.2, at 37 °C for 1 h. An additional 3.7 mg of the enzyme was then added, and the incubation was continued for 24 h. The digest was applied onto a Toyopearl HW-40F column (2.2 × 100 cm), and glycopeptides were eluted with 0.2 M ammonium acetate buffer, pH 6.0.

Preparation of PA Sugar Chains-- PA sugar chains were prepared and purified according to the reported method (18). A freeze-dried glycopeptide fraction was heated with 1.6 ml of anhydrous hydrazine at 60 °C for 50 h followed by N-acetylation with 3.2 ml of saturated sodium bicarbonate solution and 128 µl of acetic anhydride. After desalting with Dowex 50 (H+), the solution was freeze-dried, and the residue was pyridylaminated with 160 µl of 2-aminopyridine reagent and 560 µl of reducing reagents prepared as reported (18). Excess reagents were evaporated three times with 50 µl of toluene:methanol (1:1) under a stream of nitrogen at 60 °C for 10 min.

HPLC of PA Sugar Chains-- HPLC was carried out using the following elution conditions. PA sugar chains were detected by fluorescence (excitation wavelength, 320 nm; emission wavelength, 400 nm).

Elution Condition 1 for PA O-linked sugar chains: column, Cosmosil 5C18-AR300; flow rate, 2 ml/min at 25 °C; eluent, 20 mM ammonium acetate buffer, pH 6.0, containing 0.01% 1-butanol. After injecting a sample, the butanol concentration was increased linearly from 0.01 to 0.52% in 51 min and then to 1.0% in 12 min.

Elution Condition 2 for methylation analysis: column, µBondasphere 5C18-300Å; flow rate, 1.0 ml/min at 25 °C; eluent, 0.1 M ammonium acetate buffer, pH 6.0. After injecting a sample, the acetonitrile concentration was increased linearly from 0 to 70% in 45 min.

Size fractionation HPLC: column, Shodex NH2P-50; flow rate, 0.6 ml/min at 25 °C. Two eluents, A and B, were used. Eluent A was acetonitrile:water:acetic acid (95:5:3, v/v/v) titrated to pH 7.3 with triethylamine, and Eluent B was water:acetic acid (100:3, v/v) titrated to pH 7.3 with triethylamine. The column was equilibrated with Eluent A. Three min after injecting a sample, linear gradient elution was performed to Eluent A:Eluent B (90:10, v/v) in 2 min and then to Eluent A:Eluent B (50:50 v/v) in 38 min.

Anion-exchange HPLC: column, TSKgel Sugar AXI; flow rate, 0.3 ml/min at 73 °C. The eluent used was a mixture of 9 parts 0.8 M boric acid adjusted to pH 9.0 with potassium hydroxide and 1 part acetonitrile.

Mono Q HPLC: column, Mono Q HR 5/5; flow rate 1.0 ml/min at 25 °C. The eluent used was water titrated to pH 9.0 with aqueous ammonia. Adsorbed samples were eluted with a linear gradient of ammonium sulfate from 0 to 1.0 M concentration.

Exoglycosidase Digestion-- A PA sugar chain (100 pmol) was digested with 100 milliunits of Aspergillus beta -galactosidase in 20 µl of 50 mM ammonium acetate buffer, pH 4.5; with 2.5 milliunits of sialidase in 50 µl of 100 mM ammonium acetate buffer, pH 5.0; or with 100 units of beta -glucuronidase in 100 µl of 200 mM ammonium acetate buffer, pH 5.0. Enzymatic reactions were carried out at 37 °C for 16 h and then terminated by heating at 100 °C for 3 min.

Methanolysis-- A PA sugar chain (500 pmol) was methanolyzed with 50 mM HCl in methanol at 37 °C for 3 h (19). After evaporation to dryness, the desulfated PA sugar chain was N-acetylated with 120 µl of water:pyridine:acetic anhydride (5:25:1) on ice for 1 h. After evaporation of the solution, a small amount of O-acetyl groups was removed by heating the solution with 20 µl of 1.0 M aqueous ammonia at 100 °C for 5 min. The solution was then freeze-dried.

Methylation Analysis-- Freeze-dried X2 (2 nmol) was permethylated with 0.1 ml of methylsulfinyl carbanion reagent (prepared from 25 mg of NaH and 0.8 ml of dimethyl sulfoxide) and 0.1 ml of methyl iodide as reported (20). The reaction mixture was placed on a Sephadex LH 20 column (0.9 × 24 cm), and the permethylated X2 was eluted with chloroform. One-ml fractions were collected, and each fraction was concentrated to dryness by blowing the solvent with nitrogen. The residue was dissolved in a small amount of chloroform, and the sample was purified by TLC using a silica gel plate and methanol:ethyl acetate (2:8, v/v) with one drop of acetic acid as a solvent. The fluorescent spots revealed under a UV lamp were scraped and combined, and the permethylated X2 was extracted with 2 ml of methanol. The extract was evaporated to dryness, and the permethylated X2 thus purified was then hydrolyzed with 50 µl of 4 M trifluoroacetic acid at 100 °C for 3 h. The solution was freeze-dried, and the residue was pyridylaminated with 10 µl of 2-aminopyridine reagent and 35 µl of borane-dimethylamine complex reagent as reported (21). Excess reagents were evaporated three times with 50 µl of toluene:methanol (1:1 v/v) under a stream of nitrogen at 60 °C for 10 min (18). The residue was dissolved in 5 µl of the electrophoresis buffer, and small amounts of contaminating materials were removed by paper electrophoresis. Paper electrophoresis was performed at 30 V/cm at 4 °C using a filter paper (30 cm) and water:acetic acid:pyridine (60:2:3, v/v). The area that migrated like PA GlcNAc was cut off, and PA derivatives of partially O-methylated PA monosaccharides were extracted from the paper 4 times each with 100 µl of water. A part of the solution (10 µl) was analyzed by reversed-phase HPLC using Elution Condition 2.

Mass Spectrometric Analysis-- Mass spectra were recorded using a Voyager-DE STR BioSpectrometry Workstation, a matrix-assisted laser desorption ionization time of flight mass spectrometer (PerSeptive Biosystems, Framingham, MA). For mass spectrometry, PA sugar chains were dissolved in distilled water (10 pmol/µl). Aliquots of 0.5 µl were applied onto a sample plate. Subsequently, 0.5 µl of a matrix solution (10 mg/ml 2, 5-dihydroxybenzoic acid in 50% (v/v) acetonitrile) was mixed with the aliquot and allowed to dry. The analyzer was used in the linear mode.

Nuclear Magnetic Resonance (NMR) Spectroscopy-- PA sugar chains were exchanged twice with 2H2O at room temperature with intermediate lyophilization and finally dissolved in 2H2O (99.999 atom % 2H; Isotec, Miamisburg, OH). Samples were analyzed at 30 or 50 °C on a Varian Unity Inova 750 MHz NMR spectrometer. Chemical shifts (delta ) are expressed by reference to internal acetone (delta  2.213 ppm at 50 °C, delta  2.218 ppm at 30 °C).

Equilibrium Dialysis-- A commercial HNK-1 monoclonal antibody was purified by gel filtration on a YMC-Pack Diol-200G column, and the IgM fraction was concentrated by ultrafiltration with an Amicon YM-30 membrane. Equilibrium dialysis was performed between 60 µl each of an antibody solution and an oligosaccharide solution using a Spectrapor membrane at 2 °C for 48 h (22). Three concentrations of X1 (160, 80, and 40 nM) and one concentration of X2 (80 nM) were used. PA GlcNAc was employed as an internal standard. After the dialysis, a part of the oligosaccharide fraction was removed, and the amounts of X1 and X2 were quantified by size fractionation HPLC. The binding constant was obtained by double-reciprocal plots of the concentration of the bound oligosaccharide versus that of the free oligosaccharide, as reported (23).

Other Analytical Methods-- The structures of the PA sugar chains were assessed by two-dimensional sugar mapping. A PA sugar chain was chromatographed by reversed-phase (Elution Condition 1) and size fractionation HPLC, and its elution position was compared with those of standard PA sugar chains on a two-dimensional sugar map. The PA sugar chain was then digested sequentially with exoglycosidases, and the structure of the product was analyzed on the two-dimensional sugar map as reported (23).

The reducing ends of PA sugar chains were analyzed according to the reported method (24). PA sugar chains were hydrolyzed with 100 µl of 4 M trifluoroacetic acid at 100 °C for 3 h in evacuated sealed tubes. The solution was evaporated to dryness by a centrifugal concentrator, and the residue was N-acetylated with saturated sodium bicarbonate solution and acetic anhydride. The PA monosaccharides obtained were separated and quantified by anion-exchange HPLC.

Component sugar analysis was done as reported (24). Glycopeptides were hydrolyzed with 100 µl of 4 M trifluoroacetic acid at 100 °C for 3 h. The solution was freeze-dried, and monosaccharides liberated were N-acetylated with saturated sodium bicarbonate solution and acetic anhydride. After desalting with Dowex 50 (H+), the solution was freeze-dried, and the monosaccharides were pyridylaminated with 2-aminopyridine and borane-dimethylamine complex. The excess reagents were removed under a stream of nitrogen gas with 40 µl of toluene at 40 °C. The residue was dissolved in a small amount of water, and a part of the solution was analyzed by anion-exchange HPLC.

Sulfate ion was measured by ion chromatography. A PA sugar chain (2 nmol) was mixed with 20 µl of 20 mM sodium hydroxide. After heating at 250 °C for 30 min, the resulting sulfate ion was measured with a Dionex 20210i ion chromatography system using an IonPac AS4A column and 2.8 mM Na2CO3, 2.25 mM NaHCO3 at a flow rate of 1.5 ml/min (25). Sialic acid was measured by the reported method (26).

    RESULTS

Preparation and Analysis of a PA Sugar Chain Fraction from uTM-- Glycopeptides were prepared from 374 mg of uTM by digestion with actinase E, and the digest was purified by gel filtration. After component analysis of each fraction, the fractions that contained sugars were combined (data not shown). Sugar chains were liberated from the combined fraction by hydrazinolysis followed by N-acetylation, and the reducing ends of the sugar chains were pyridylaminated. To obtain an overall view of the sugar structures, the reducing ends of the PA sugar chain fraction were first analyzed. The acid hydrolysates of the PA sugar chain fraction were found to contain 0.39 µmol of PA Xyl, 3.0 µmol pf PA GlcNAc, 0.45 µmol of PA GalNAc, and 0.39 µmol of PA Gal (from a by-product obtained from Gal-GalNAc structures during the preparation (18)), indicating that a sugar chain containing Xyl at the reducing end comprised about 8% (mol/mol) of the total sugar chains. Detection of PA Xyl indicated the presence of proteoglycan-type sugar chains; however, the linking of chondroitin sulfate chains was excluded as judged from the finding that the uTM bands on SDS-polyacrylamide electrophoresis gels were not changed by digestion with chondroitinase ABC (data not shown). The PA sugar chain fraction was digested with sialidase and analyzed by Mono Q HPLC, and a pass-through and adsorbed fractions were obtained. Reducing-end analysis of each fraction revealed that PA Xyl was present only in the acid hydrolysates of the adsorbed fraction, indicating that the xylose-containing sugar chains carried a negative charge(s) in addition to sialic acid (data not shown).

Purification of PA Sugar Chains with Xylose at the Reducing Ends-- The PA sugar chain fraction was applied onto a TSKgel HW-40F column, and an aliquot of each fraction was subjected to reducing-end PA monosaccharide analysis (Fig. 1). A fraction containing PA Xyl (Fraction X) was collected and further fractionated by reversed-phase HPLC (Fig. 2). Reducing-end analysis of each peak showed that fractions X1 and X2 contained a PA Xyl residue as a major component. The other fractions and the fraction eluted between 25 and 60 ml did not contain appreciable amounts of PA Xyl. Other major peaks contained PA GalNAc, PA Gal, or PA GlcNAc as major components. Small amounts of contaminating materials were removed by size fractionation HPLC, and the final fractions were desalted on a Sephadex G-25 column (1 × 10 cm) using 10 mM ammonium acetate, pH 6.0, as an eluent. Starting from Fraction X, X1, and X2 were recovered at 17 and 26% (including losses during purification), respectively. X1 and X2 thus purified showed a single peak when analyzed by reversed-phase HPLC (data not shown) using Elution Condition 1 and size fractionation HPLC, indicating that X1 and X2 were pure.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   Gel filtration profiles of PA sugar chains from uTM. PA sugar chains were applied onto a TSKgel HW-40F column (2 × 80 cm) using 0.2 M ammonium acetate buffer, pH 6.0, and 5-ml fractions were collected. An aliquot of each fraction was subjected to reducing-end PA sugar analysis. , PA GlcNAc; triangle , PA GalNAc; open circle , PA Xyl. Fractions indicated by a bar were pooled as Fraction X.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Subfractionation of Fraction X by reversed-phase HPLC. Elution Condition 1 was used (see text).

Structure Analysis of X1-- The fluorescent fragments obtained by partial acid hydrolysis (100 °C in 1 M trifluoroacetic acid for 15 min) of X1 appeared at the elution positions of GlcAbeta 1-3Galbeta 1-3Galbeta 1-4Xyl-PA, Galbeta 1-4Xyl-PA, and PA Xyl on a two-dimensional sugar map (Fig. 3), indicating that X1 contained the linkage tetrasaccharide structure of proteoglycans. X1 had 1 mol of sulfate but no sialic acid (Table I). The elution position of X1 on the map was not changed by digestion with beta -glucuronidase, chondro-4-sulfatase, or chondro-6-sulfatase (data not shown). When X1 was desulfated by methanolysis, the product appeared at the position of GlcAbeta 1-3Galbeta 1-3Galbeta 1-4Xyl-PA (Fig. 3). X1 was not digested with beta -glucuronidase, but desulfated X1 was then susceptible to beta -glucuronidase digestion. These results indicated that the sulfate group was linked to the GlcA-Gal structure. On further digestion of the beta -glucuronidase digest (position D) with Aspergillus beta -galactosidase, a new peak appeared at PA Xyl. These results suggested that X1 was SO4-GlcAbeta 1-3Galbeta 1-3Galbeta 1-4Xyl-PA.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   Characterization of structures of X1 and X2 using a two-dimensional sugar map. The elution positions relative to that of Galbeta 1-3GalNAc-PA on reversed-phase HPLC are shown on the abscissa. Elution Condition 1 was used for the reversed-phase HPLC. The molecular sizes of the PA sugar chains measured by size fractionation HPLC are plotted on the ordinate in terms of glucose units using PA isomaltooligosaccharides. Arrows with solid lines indicate changes in coordinate positions caused by chemical desulfation, and other arrows indicate changes in coordinate positions caused by digestion with the following exoglycosidases: dashed lines, beta -glucuronidase; dot and dash line; beta -galactosidase; dotted line, sialidase. AGGX, GlcAbeta 1-3Galbeta 1-3Galbeta 1-4Xyl-PA; GX, Galbeta 1-4Xyl-PA.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Component analysis of Fractions X1 and X2
Reducing end PA Xyl was measured as described under "Experimental Procedures." Sulfate ion was measured by ion chromatography after heating with sodium hydroxide at 250 °C for 30 min. Neu5Ac was quantified by the method of Hara et al. (26). The value of PA Xyl was taken as 1.00.

The above findings were confirmed by measuring the molecular weight of X1 by mass spectrometry (Fig. 4). In the positive-ion mass spectrum, the peak of the molecule-related ion, [M + Na]+ (m/z 831.2, calculated 831.2), was observed. Loss of sodium sulfite with hydrogen transfer from the cation also occurred, resulting in an intense peak at m/z 729.2 (calculated 729.3). In the negative-ion mass spectrum also, the results verified the proposed structures of X1. The linkage position of the sulfate group was analyzed by 1H NMR spectroscopy. Reported data on the unsaturated linkage hexasaccharide of proteoglycans (Delta GlcAbeta 1-3GalNAcbeta 1-4GlcAbeta 1-3Galbeta 1-3Galbeta 1-4Xylol) (27), the synthetic trisaccharide, YM677 (SO4-3GlcAbeta 1-3Galbeta 1-4GlcNAc) (28), and an oviducal mucin oligosaccharide (SO4-3GlcAbeta 1-3Galbeta 1-4Galbeta 1-3GalNAcol) (29) provided the necessary reference data for assignment of the proton signals of X1 (Table II). The proton signal at 4.605 ppm was assigned to H1 of Gal-2 and that at 4.668 ppm, to H1 of Gal-3 as compared with those of the unsaturated linkage hexasaccharide (R1). Analysis of the two-dimensional NMR spectra of the SO4-GlcA residues in X1 (Fig. 5) revealed identical spin patterns to the SO4-3GlcA residues in the the synthetic trisaccharide, YM677 (R2) and oviducal mucin oligosaccharide (R3). Therefore, the proton signals at 4.757 and 4.317 ppm were, respectively, assigned to H1 and H3 of SO4-3GlcA, confirming that the HNK-1 disaccharide element was present in X1. Taking these results together with those given above, the structure of X1 was determined to be SO4-3GlcAbeta 1-3Galbeta 1-3Galbeta 1-4Xyl-PA.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Matrix-assisted laser desorption ionization mass spectra of Fraction X1 and X2. a and b, X1; c and d, X2. a and c, positive-ion mode; b and d, negative-ion mode.

                              
View this table:
[in this window]
[in a new window]
 
Table II
1H chemical shifts of structural-reporter groups of constituent monosaccharides of X1, X2, and reference compounds
X2, SO4-3GlcA[4]beta 1-3Gal[3]beta 1-3(Neu5Acalpha 2-6)Gal[2]beta 1-4Xyl-PA[1]; X1, SO4-3GlcA[4]beta 1-3Gal[3]beta 1-3Gal[2]beta 1-4Xyl-PA[1]; R1, Delta GlcAbeta 1-3GalNAcbeta 1-4GlcA[4]beta 1-3Gal[3]beta 1-3Gal[2]beta 1-4Xylol (27); R2, SO4-3GlcA[4]beta 1-3Gal[3]beta 1-4GlcNAc (28); R3, SO4-3GlcA[4]beta 1-3Gal[3]beta 1-4Galbeta 1-3GalNAcol (29). Code numbers of sugar residues are indicated in brackets as described above. X1 was measured at 50 °C, X2 at 50 and 30 °C, R1 at 15 °C, R2 at 22 °C, and R3 at 27 °C.


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 5.   Analysis of sugar structures of Fraction X1 and X2 by total correlated spectroscopy. Parts of the total correlated spectroscopy spectra of X1 (A) and X2 (B) are shown. Specific spin patterns observed for GlcA are shown by dashed lines.

Structure Analysis of X2-- Partial acid hydrolysis of X2 gave the same fluorescent fragments as found for X1, indicating that X2 also contained the linkage tetrasaccharide structure. X2 had 1 mol each of a sulfate and Neu5Ac (Table I). The sialidase digest of X2 was eluted at the position of X1 on the two-dimensional sugar map (Fig. 3), indicating that X2 was a sialylated form of X1. The elution position of X2 on the map was also not changed by digestion with beta -glucuronidase, chondro-4-sulfatase, or chondro-6-sulfatase (data not shown). When X2 was desulfated by methanolysis, the product appeared at position A (Fig. 3). Desulfated X2 was then susceptible to beta -glucuronidase digestion, and the digest was eluted at position B. These results indicated that the sulfate group was linked to the GlcA-Gal structure. On further digestion of the beta -glucuronidase digest with Aspergillus beta -galactosidase, a new peak with a molecular size 0.9 glucose units smaller appeared at position C. The sialidase digest of the beta -galactosidase digest was eluted at the position of Galbeta 1-4Xyl-PA, indicating that Neu5Ac was linked to the Gal-Xyl structure (Fig. 3). Methylation analysis of X2 indicated 3,6-disubstituted and 3-substituted Gal structures (Fig. 6). These results suggested that X2 was SO4-GlcAbeta 1-3Galbeta 1-3(Neu5Acalpha 2-6)Galbeta 1-4Xyl-PA. The structure was confirmed by measuring the molecular weight of X2 by mass spectrometry (Fig. 4). In the positive-ion mass spectrum, peaks of the molecule-related ions, [M + Na]+ (m/z 1122.2, calculated 1122.3) and [M + K]+ (m/z 1138.5, calculated 1138.3), were observed. Loss of sodium sulfite with hydrogen transfer from these cations also occurred, resulting in an intense peak at m/z 1020.2 (calculated 1020.4). In the negative-ion mass spectrum also, the results verified the proposed structure of X2. The linkage position of the sulfate group was analyzed by 1H NMR in the same manner as for X1. Analysis of the two-dimensional NMR spectra of the SO4-GlcA residue in X2 (Fig. 5) revealed identical spin patterns to the SO4-3GlcA residues in X1. Therefore, the proton signal at 4.756 ppm and that at 4.320 ppm were, respectively, assigned to H1 and H3 of SO4-3GlcA, confirming that the HNK-1 disaccharide element was also present in X2. Three typical signals (H3e 2.688, H3a 1.634, and NAc 2.012 ppm) of the Neu5Ac residue were observed. The NMR spectra of X2 were almost the same as those of X1 besides Neu5Ac and H4 of Gal-2. The H4 signal of Gal-2 in X1 was shifted, indicating that Neu5Ac was linked to C6 of Gal-2. Taking these results together with those given above, the structure of X2 is SO4-3GlcAbeta 1-3Galbeta 1-3(Neu5Acalpha 2-6)Galbeta 1-4Xyl-PA.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 6.   Reversed-phase HPLC of partially O-methylated PA sugars obtained by methylation analysis of Fraction X2. Arrows indicate the elution positions of the derivatives of PA galactose: 1, 3,4-di-O-methyl; 2, 2,3-di-O-methyl and 2,6-di-O-methyl; 3, 3,6-di-O-methyl; 4, 4,6-di-O-methyl; 5, 2,4-di-O-methyl; 6, 3,4,6-tri-O-methyl; 7, 2,3,6-tri-O-methyl; 8, 2,3,4-tri-O-methyl; 9, 2,4,6-tri-O-methyl; 10, 2,3,4,5-tetra-O-methyl. Arrow A indicates the elution position of the derivative obtained from the reducing-end PA xylose.

Binding Analysis of HNK-1 Antibody to X1 and X2-- Double-reciprocal plots of the concentrations of the bound oligosaccharide (X1) versus those of the free oligosaccharide in equilibrium dialysis gave the binding constant of HNK-1 antibody to X1. The apparent association constant was 2.5 × 106 M-1. The binding constant of X2, 1 × 106 M-1, was smaller than that of X1. These analyses showed that Neu5Ac in X2 did not contribute to the binding to the antibody used.

    DISCUSSION

Analysis of sugar chains from human uTM revealed the presence of oligosaccharides with xylose at the reducing end. On the basis of the results obtained with X1 and X2, the structures were determined to be linkage tetrasaccharides of proteoglycans with SO4-3GlcA at the nonreducing end and with partial substitution of sialic acid. These are novel structures and to our knowledge are the first reported instance of a proteoglycan linkage tetrasaccharide with SO4-3GlcA and sialic acid residues solely linked to a glycoprotein. Because X1 and X2 were liberated and their structures determined by chemical means, the possibility of another chemically labile substituent(s) cannot be excluded. uTM does not contain chondroitin sulfate (2-4), although TM produced in cultured human endothelial cells and recombinant TMs were expressed in both cases with a high molecular weight TM containing chondroitin sulfate and a low molecular weight TM lacking this modification (10). Platelet factor 4 binds to the glycanated form of TM but not to the chondroitin sulfate-lacking TM (12). Acceleration of the inhibition of thrombin by antithrombin III by TM is dependent upon the presence of chondroitin sulfate linked to TM (10). Hence, the binding of chondroitin sulfate seems to be important for several of the versatile functions of TM and to affect its cell-surface anticoagulant potential. Chondroitin sulfate is linked to Ser-474 in the high molecular weight TM of recombinant TM, but Ser-474 is also modified with a small substituent in the low molecular weight TM (9, 10). By way of explanation of the fact that TM is expressed in two distinct forms, Gerlitz et al. (9) postulated a model involving glycosyltransferase competition between xylosyltransferase and N-acetylgalactosaminyltransferase for Ser-474, whereas Lin et al. (10) suggested that occupation of the adjacent O-linked glycosylation may be important because of the steric hindrance for xylosyltransferase of the cell line.

If the new structures determined in the present paper link to a similar position, the following possibilities arise. The key step in producing the low molecular weight TM is the first GalNAc transfer reaction to the proteoglycan linkage tetrasaccharide regulated by sulfation at 3C of GlcA, which leads to regulation of the cell-surface anticoagulant potential. This is compatible with the finding that GalNAc transferase catalyzing chondroitin chain elongation cannot transfer GalNAc to 3-O-sulfated GlcA (30). This sulfation may be accomplished either with a similar sulfotransferase, as reported for the detection of SO4-3GlcAbeta 1-4Xylbeta -4-methylumbelliferone from the substrate, 4-methylumbelliferyl beta -Xyl (31), or with the sulfotransferase involved in the biosynthesis of the HNK-1 carbohydrate epitope (32, 33). These results suggest that glycosaminoglycan chain elongation of human TM seems to be abolished at the linkage tetrasaccharide core structure by addition of a sulfate group, indicating that 3-O-sulfation is a stop signal leading to TM lacking chondroitin sulfate.

    ACKNOWLEDGEMENTS

We are grateful to Dr. K. Lee (Osaka University, Graduate School of Science) for operation of the Varian 750-MHz NMR spectrometer of the Venture Business Laboratory, Osaka University and Koutarou Hoshida for operation of the mass spectrometer.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Pharmaceutical Laboratory, Mocida Pharmaceutical Co., Ltd., Fujieda, Shizuoka 426-8640, Japan.

Present address: Pharmaceutical Development Laboratory, Kirin Brewery Co., Takasaki, Gunma 370, Japan.

Dagger Dagger To whom correspondence should be addressed.: Tel: +81-6-6850-5380; Fax: +81-6-6850-5383.

    ABBREVIATIONS

The abbreviations used are: TM, thrombomodulin; uTM, urinary soluble TM; PA, pyridylaminated; HPLC, high performance liquid chromatography.

    REFERENCES
Top
Abstract
Introduction
References
  1. Esmon, C. T. (1995) FASEB J. 9, 946-955[Abstract/Free Full Text]
  2. Yamamoto, S., Mizoguchi, T., Tamaki, T., Ohkuchi, M., Kimura, S., and Aoki, N. (1993) J. Biochem. (Tokyo) 113, 433-440[Abstract]
  3. Jackson, D. E., Tetaz, T. J., Salem, H. H., and Mitchell, C. A. (1994) Eur. J. Biochem. 221, 1079-1087[Abstract]
  4. Nakano, M., Furutani, M., Hiraishi, S., and Ishii, H. (1998) Thromb. Haemostasis 79, 331-337[Medline] [Order article via Infotrieve]
  5. Takahashi, Y., Hosaka, Y., Niina, H., Nagasawa, K., Naotsuka, M., Sakai, K., and Uemura, A. (1995) Thromb. Haemostasis 73, 805-811[Medline] [Order article via Infotrieve]
  6. Takahashi, Y., Hosaka, Y., Imada, K., Adachi, T., Niina, H., Watanabe, M., and Mochizuki, H. (1997) Thromb. Haemostasis 77, 789-795[Medline] [Order article via Infotrieve]
  7. Suzuki, K., Kusumoto, H., Deyashiki, Y., Nishioka, J., Maruyama, I., Zushi, M., Kawahara, S., Honda, G., Yamamoto, S., and Horiguchi, S. (1987) EMBO J. 6, 1891-1897[Abstract]
  8. Parkinson, J. F., Vlahos, C. J., Yan, S. C. B., and Bang, N. U. (1992) Biochem. J. 283, 151-157[Medline] [Order article via Infotrieve]
  9. Gerlitz, B., Hassell, T., Vlahos, C. J., Parkinson, J. F., Bang, N. U., and Grinnell, B. W. (1993) Biochem. J. 295, 131-140[Medline] [Order article via Infotrieve]
  10. Lin, J-H., McLean, K., Morser, J., Young, T. A., Wydro, R. M., Andrews, W. H., and Light, D. R. (1994) J. Biol. Chem. 269, 25021-25030[Abstract/Free Full Text]
  11. Nawa, K., Sakano, K., Fujiwara, H., Sato, Y., Sugiyama, N., Teruuchi, T., Iwamoto, M., and Marumoto, Y. (1990) Biochem. Biophys. Res. Commun. 171, 729-737[Medline] [Order article via Infotrieve]
  12. Dudek, A. Z., Pennell, C. A., Decker, T. D., Young, T. A., Key, N. S., and Slungaard, A. (1997) J. Biol. Chem. 272, 31785-31792[Abstract/Free Full Text]
  13. Gysin, J., Pouvelle, B., Tonqueze, M. L., Edelman, L., and Boffa, M-C. (1997) Mol. Biochem. Parasitol. 88, 267-271[CrossRef][Medline] [Order article via Infotrieve]
  14. Rogerson, S. J., Novakovic, S., Cooke, B. M., and Brown, G. V. (1997) Exp. Parasitol. 86, 8-18[CrossRef][Medline] [Order article via Infotrieve]
  15. Edano, T., Kumai, N., Mizoguchi, T., and Ohkuchi, M. (1998) Int. J. Biochem. Cell Biol. 30, 77-88[CrossRef][Medline] [Order article via Infotrieve]
  16. Makino, Y., Kuraya, N., Omichi, K., and Hase, S. (1996) Anal. Biochem. 238, 54-59[CrossRef][Medline] [Order article via Infotrieve]
  17. Hase, S., Ikenaka, T., and Matsushima, Y. (1978) Biochem. Biophys. Res. Commun. 85, 257-263[Medline] [Order article via Infotrieve]
  18. Kuraya, N., and Hase, S. (1992) J. Biochem. 112, 122-126[Abstract]
  19. Slomiany, A., Kojima, K., Banas-Gruszka, Z., and Slomiany, B. L. (1981) Biochem. Biophys. Res. Commun. 100, 778-784[Medline] [Order article via Infotrieve]
  20. Hakomori, S. (1964) J. Biochem. (Tokyo) 55, 205-208[Medline] [Order article via Infotrieve]
  21. Hase, S. (1994) Methods Enzymol. 230, 225-237[Medline] [Order article via Infotrieve]
  22. Mega, T., and Hase, S. (1991) J. Biochem. (Tokyo) 109, 600-603[Abstract]
  23. Mega, T., Oku, H., and Hase, S. (1992) J. Biochem. (Tokyo) 111, 396-400[Abstract]
  24. Hase, S., Hatanaka, K., Ochiai, K., and Shimizu, H. (1992) Biosci. Biotechnol. Biochem. 56, 1676-1677
  25. Sugahara, K., Masuda, M., Yamada, S., Harada, T., Yoshida, K., and Yamashita, I. (1989) in Proceedings of the 10th International Symposium on Glycoconjugates, Sept. 10, 1989 (Sharon, N., Lis, H., Duskin, D., and Kahane, I., eds), p. 322, Jerusalem, Israel
  26. Hara, S., Takemori, Y., Yamaguchi, M., Nakamura, M., and Ohkura, Y. (1987) Anal. Biochem. 164, 138-145[Medline] [Order article via Infotrieve]
  27. Sugahara, K., Ohi, Y., Harada, T., de Waard, P., and Vliegenthart, J. F. G. (1992) J. Biol. Chem. 267, 6027-6035[Abstract/Free Full Text]
  28. Voshol, H., van Zuylen, C. W. E. M., Orberger, G., Vliegenthart, J. F. G., and Schachner, M. (1996) J. Biol. Chem. 271, 22957-22960[Abstract/Free Full Text]
  29. Florea, D., Maes, E., and Strecker, G. (1997) Carbohydr. Res. 302, 179-189[CrossRef][Medline] [Order article via Infotrieve]
  30. Kitagawa, H., Tsutsumi, K., Ujikawa, M., Goto, F., Tamura, J., Neumann, K. W., Ogawa, T., and Sugahara, K. (1997) Glycobiology 7, 531-537[Abstract]
  31. Takagaki, K., Tazawa, T., Munakata, H., Nakamura, T., and Endo, M. (1997) J. Biochem. (Tokyo) 122, 1129-1132[Abstract]
  32. Bakker, H., Friedmann, I., Oka, S., Kawasaki, T., Nifant'ev, N., Schachner, M., and Mantei, N. (1997) J. Biol. Chem. 272, 29942-29946[Abstract/Free Full Text]
  33. Ong, E., Yeh, J-C., Ding, Y., Hindsgaul, O., and Fukuda, M. (1998) J. Biol. Chem. 273, 5190-5195[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.